Trials / Recruiting
RecruitingNCT05942456
Soluble B7-H3 as a Biomarker for Osteosarcoma
An Exploratory Research of Soluble B7-H3 Expression in Peripheral Blood as a Biomarker to Monitor Therapeutic Effect of Systemic Treatment for Osteosarcoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ELISA: enzyme-linked immunosorbent assay | enzyme-linked immunosorbent assay |
Timeline
- Start date
- 2023-06-05
- Primary completion
- 2024-07-01
- Completion
- 2024-12-31
- First posted
- 2023-07-12
- Last updated
- 2024-05-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05942456. Inclusion in this directory is not an endorsement.